The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
Open accessAbstract
INTRODUCTION: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection). We searched Medline, Embase, and the Cochrane Library up to May 2014 to identify eligible studies in adult patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis that evaluated anti-TNF drugs compared with placebo or no treatment. Expert opinion: Our study encompassed data from 71 randomized controlled trials involving 22,760 participants (range of follow-up: 1-36 months) and seven open label extension studies with 2,236 participants (range of follow-up: 6-48 months). Quantitative synthesis of the available data found statistically significant increases in the occurrence of any infections (20%), serious infections (40%), and tuberculosis (250%) associated with anti-TNF drug use, while the data for opportunistic infections were scarce. The quality of synthesized evidence was judged as moderate. Further evidence from registries and long-term epidemiological studies are needed to better define the relationship between anti-TNF agents and infection complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We used two techniques to calculate the pooled effect estimates: the fixed-effects model (MantelHaenszel approach [18]) and the random-effects model (DerSimonian & Laird approach [19]).”
MethodPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · cited 1×
“We used two techniques to calculate the pooled effect estimates: the fixed-effects model (MantelHaenszel approach [18]) and the random-effects model (DerSimonian & Laird approach [19]).”
MethodCochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380 · cited 1×
“The between-study heterogeneity was evaluated using Cochran’s Q test [24] with a 0.”
MethodCochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734 · cited 2×
“5 in a setting of sparse data and imbalanced study groups [17].”
BackgroundTumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
St. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Gómez‐Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., & Montero, M. D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11137 · Cited by 1,013
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis
Petitti, D. B. (1999) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195133646.001.0001 · Cited by 925
Mease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20335 · Cited by 882
van der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., & Braun, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20852 · Cited by 860
Emery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., Singh, A., Pedersen, R. D., Koenig, A. S., & Freundlich, B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61000-4 · Cited by 821
Davis, J. C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D. O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11325 · Cited by 754
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.118935 · Cited by 715
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
Antoni, C., Krueger, G. G., de Vlam, K., Birbara, C., Beutler, A., Guzzo, C., Zhou, B., Dooley, L. T., & Kavanaugh, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032268 · Cited by 715
Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
Gorman, J. D., Sack, K. E., & Davis, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012664 · Cited by 704
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Antoni, C. E., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G. R., Schneider, U., Furst, D. E., Molitor, J., Keystone, E., Gladman, D., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20967 · Cited by 640
Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Kavanaugh, A., McInnes, I., Mease, P., Krueger, G. G., Gladman, D., Gomez‐Reino, J., Papp, K., Zrubek, J., Mudivarthy, S., Mack, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24403 · Cited by 602
Inman, R. D., Davis, J. C., Heijde, D. V. D., Diekman, L., Sieper, J., Kim, S. I., Mack, M., Han, J., Visvanathan, S., Xu, Z., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23969 · Cited by 593
Keystone, E., Heijde, D. V. D., Mason, D., Landewé, R., Vollenhoven, R. V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23964 · Cited by 576
Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., Pazdur, J., Bae, S.-C., Palmer, W., Zrubek, J., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099010 · Cited by 541
Schiff, M., Keiserman, M., Codding, C., Songcharoen, S., Berman, A., Nayiager, S., Saldate, C., Li, T., Aranda, R., Becker, J.-C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080002 · Cited by 539
Sieper, J., van der Heijde, D., Dougados, M., Mease, P. J., Maksymowych, W. P., Brown, M. A., Arora, V., & Pangan, A. L. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201766 · Cited by 536
Wolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 534
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Furst, D., Weisman, M. H., St.Clair, E. W., Keenan, G. F., van der Heijde, D., Marsters, P. A., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20159 · Cited by 514
Furst, D. E., Schiff, M. H., Fleischmann, R., Strand, V., Birbara, C. A., Compagnone, D., Fischkoff, S. A., & Chartash, E. (2003) · PubMed · Cited by 495
Wolfe, F., Caplan, L., & Michaud, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 480
Landewé, R., Braun, J., Deodhar, A. A., Dougados, M., Maksymowych, W. P., Mease, P. J., Reveille, J. D., Rudwaleit, M., van der Heijde, D. M. F. M., Stach, C. M., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204231 · Cited by 470
TREATMENT OF ANKYLOSING SPONDYLITIS BY INHIBITION OF TUMOR NECROSIS FACTOR a
Orman, D., Enneth, K., Ack, E. S., Ohn, J., & Avis, C. D. (2002) · Cited by 470
Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sörensen, H., Grassnickel, L., Rudwaleit, M., Sieper, J., & Braun, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11017 · Cited by 458
Geborek, P., Bladström, A., Turesson, C., Gulfe, A., Petersson, I. F., Saxne, T., Olsson, H., & Jacobsson, L. T. H. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030528 · Cited by 427
Mariette, X., Matucci-Cerinic, M., Pavelka, K., Taylor, P., van Vollenhoven, R., Heatley, R., Walsh, C., Lawson, R., Reynolds, A., & Emery, P. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.149419 · Cited by 404
Emery, P., Fleischmann, R. M., Moreland, L. W., Hsia, E. C., Strusberg, I., Durez, P., Nash, P., Amante, E. J. B., Churchill, M., Park, W., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24638 · Cited by 398
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398
Fleischmann, R., Cutolo, M., Genovese, M. C., Lee, E. B., Kanik, K. S., Sadis, S., Connell, C. A., Gruben, D., Krishnaswami, S., Wallenstein, G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33383 · Cited by 376
Leombruno, J. P., Einarson, T. R., & Keystone, E. C. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091025 · Cited by 362
Smolen, J. S., Nash, P., Durez, P., Hall, S., Ilivanova, E., Irazoque-Palazuelos, F., Miranda, P., Park, M.-C., Pavelka, K., Pedersen, R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61811-x · Cited by 357
Van den Bosch, F., Kruithof, E., Baeten, D., Herssens, A., de Keyser, F., Mielants, H., & Veys, E. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.511 · Cited by 352
Fleischmann, R., Vencovsky, J., van Vollenhoven, R. F., Borenstein, D., Box, J., Coteur, G., Goel, N., Brezinschek, H.-P., Innes, A., & Strand, V (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099291 · Cited by 338
Haibel, H., Rudwaleit, M., Listing, J., Heldmann, F., Wong, R. L., Kupper, H., Braun, J., & Sieper, J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23606 · Cited by 316
Weisman, M. H., Moreland, L. W., Furst, D. E., Weinblatt, M. E., Keystone, E. C., Paulus, H. E., Teoh, L. S., Velagapudi, R. B., Noertersheuser, P. A., Granneman, G. R., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80164-9 · Cited by 303
Schneeweiss, S., Setoguchi, S., Weinblatt, M. E., Katz, J. N., Avorn, J., Sax, P. E., Levin, R., & Solomon, D. H. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22600 · Cited by 302
Askling, J., Fahrbach, K., Nordstrom, B., Ross, S., Schmid, C. H., & Symmons, D. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2046 · Cited by 301
Kay, J., Matteson, E. L., Dasgupta, B., Nash, P., Durez, P., Hall, S., Hsia, E. C., Han, J., Wagner, C., Xu, Z., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23383 · Cited by 295
Keystone, E. C., Schiff, M. H., Kremer, J. M., Kafka, S., Lovy, M., DeVries, T., & Burge, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20019 · Cited by 284
TNF-blocking agents and tuberculosis: new drugs illuminate an old topic
Keane, J. (2005) · Rheumatology · doi:10.1093/rheumatology/keh567 · Cited by 281
Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis
Bernatsky, S., Hudson, M., & Suissa, S. (2007) · Rheumatology · doi:10.1093/rheumatology/kem076 · Cited by 281
Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis
Setoguchi, S., Solomon, D. H., Weinblatt, M. E., Katz, J. N., Avorn, J., Glynn, R. J., Cook, E. F., Carney, G., & Schneeweiss, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22056 · Cited by 240
Carmona, L., Descalzo, M. Á., Perez-Pampin, E., Ruiz-Montesinos, D., Erra, A., Cobo, T., & Gómez-Reino, J. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067660 · Cited by 231
Kavanaugh, A., Fleischmann, R., Emery, P. E., Küpper, H., Redden, L., Guérette, B., Santra, S., & Smolen, J. S. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201247 · Cited by 225
Biologic therapies in rheumatology: lessons learned, future directions
Strand, V., Kimberly, R., & Isaacs, J. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2196 · Cited by 216
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
Ding, T., Ledingham, J., Luqmani, R., Westlake, S., Hyrich, K., Lunt, M., Kiely, P., Bukhari, M., Abernethy, R., Bosworth, A., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/keq249a · Cited by 215
Genovese, M. C., Mease, P. J., Thomson, G. T. D., Kivitz, A., Perdok, R. J., Weinberg, M. A., Medich, J., & Sasso, E. H. (2007) · PubMed · Cited by 200
Dixon, W. G., Watson, K. D., Lunt, M., Mercer, L. K., British Society For Rheumatology Biologics Register Control Centre Consortium, Hyrich, K. L., Symmons, D. P. M., & British Society for Rheumatology Biologics Register (2010) · Arthritis Care & Research · doi:10.1002/acr.20129 · Cited by 200
Kavanaugh, A., Clair, E. W. S., Wj, M., Braakman, T., & Lipsky, P. E. (2000) · PubMed · Cited by 194
Zhou, H., Jang, H., Fleischmann, R. M., Bouman‐Thio, E., Xu, Z., Marini, J. C., Pendley, C., Jiao, Q., Shankar, G., Marciniak, S. J., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006298188 · Cited by 191
Detert, J., Bastian, H., Listing, J., Weiß, A., Wassenberg, S., Liebhaber, A., Rockwitz, K., Alten, R., Krüger, K., Rau, R., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201612 · Cited by 190
van de Putte, L. B. A., Rau, R., Breedveld, F. C., Kalden, J. R., Malaise, M. G., van Riel, P. L. C. M., Schattenkirchner, M., Emery, P., Burmester, G. R., Zeidler, H., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.009563 · Cited by 176
Bejarano, V., Quinn, M., Conaghan, P. G., Reece, R., Keenan, A., Walker, D., Gough, A., Green, M., McGonagle, D., Adebajo, A., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.24106 · Cited by 174
Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
Taylor, P. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.01.005 · Cited by 169
Atzeni, F., Sarzi-Puttini, P., Botsios, C., Carletto, A., Cipriani, P., Favalli, E. G., Frati, E., Foschi, V., Gasparini, S., Giardina, A., et al. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.06.008 · Cited by 169
Salliot, C., Gossec, L., Ruyssen-Witrand, A., Luc, M., Duclos, M., Guignard, S., & Dougados, M. (2006) · Rheumatology · doi:10.1093/rheumatology/kel236 · Cited by 168
van Vollenhoven, R. F., Kinnman, N., Vincent, E., Wax, S., & Bathon, J. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30372 · Cited by 167
Thalayasingam, N., & Isaacs, J. D. (2011) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2011.10.004 · Cited by 167
Cancer morbidity in rheumatoid arthritis.
Prior, P., Symmons, D. P., Hawkins, C. F., Scott, D. L., & Brown, R. (1984) · Annals of the Rheumatic Diseases · doi:10.1136/ard.43.2.128 · Cited by 162
Dartel, S. A. A. R.-V., Fransen, J., Kievit, W., Flendrie, M., den Broeder, A. A., VISSER, H. K. A., Hartkamp, A., van de Laar, M. A. F. J., & van Riel, P. L. C. M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201338 · Cited by 156
Thompson, A., Rieder, S. W., & Pope, J. E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30310 · Cited by 147
Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S., Miranda, P. C., Pazdur, J., Bae, S., PALMER, W. R., Xu, S., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.116319 · Cited by 144
Miyasaka, N., & The CHANGE Study Investigators (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0045-0 · Cited by 144
Caspersen, S., Elkjær, M., Riis, L. B., Pedersen, N. K., Mortensen, C., Jess, T., Sarto, P., Hansen, T. S., Wewer, V., Bendtsen, F., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.05.010 · Cited by 141
Kremer, J. M., Ritchlin, C. T., Mendelsohn, A. M., Baker, D., Kim, L., Xu, Z., Han, J. S., & Taylor, P. C. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27348 · Cited by 124
Weinblatt, M. E., Fleischmann, R., Huizinga, T. W. J., Emery, P. E., Pope, J. E., Massarotti, E. M., van Vollenhoven, R., Wollenhaupt, J., Bingham, C. O., Duncan, B., et al. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes150 · Cited by 122
Tanaka, Y., Harigai, M., Takeuchi, T., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.200317 · Cited by 115
Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy
Deepak, P., Sifuentes, H., Semer, R., & Ehrenpreis, E. D. (2011) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32834bb90a · Cited by 110
Risk of tuberculosis infection in anti-TNF-α biological therapy: From bench to bedside
Xie, X., Li, F., Chen, J., & Wang, J. (2013) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2013.03.005 · Cited by 107
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two‐year period
Braun, J., Deodhar, A. A., Dijkmans, B. A. C., Geusens, P., Sieper, J., Williamson, P., Xu, W., Visvanathan, S., Baker, D., Goldstein, N. H., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.24001 · Cited by 106
Weinblatt, M. E., Bingham, C. O., Mendelsohn, A. M., Kim, L., Mack, M., Lu, J., Baker, D., & Westhovens, R. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201411 · Cited by 103
Goletti, D., Sanduzzi, A., & Delogu, G. (2014) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.140099 · Cited by 88
Self-citationMoulis, G., Sommet, A., Béné, J., Montastruc, F., Sailler, L., Montastruc, J., & Lapeyre‐Mestre, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048991 · Cited by 83
Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry
Bobbio‐Pallavicini, F., Caporali, R. F., Sarzi‐Puttini, P., Atzeni, F., Bazzani, C., Gorla, R., Marchesoni, A., Favalli, E. G., & Montecucco, C. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.07.006 · Cited by 81
Weisman, M. H., Paulus, H. E., Burch, F. X., Kivitz, A., Fierer, J., Dunn, M. E., Kerr, D. R., Tsuji, W., & Baumgartner, S. W. (2007) · Rheumatology · doi:10.1093/rheumatology/kem033 · Cited by 64
Open label extension studies: research or marketing?
Taylor, G. J., & Wainwright, P. (2005) · BMJ · doi:10.1136/bmj.331.7516.572 · Cited by 62
Takeuchi, T., Harigai, M., Tanaka, Y., Yamanaka, H., Ishiguro, N., Yamamoto, K., Miyasaka, N., Koike, T., Kanazawa, M., Oba, T., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201796 · Cited by 61
Day, R. O., & Williams, K. M. (2007) · Drug Safety · doi:10.2165/00002018-200730020-00001 · Cited by 55
Nannini, C., Cantini, F., Niccoli, L., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24506 · Cited by 42
Self-citationBonovas, S., Lytras, T., & Nikolopoulos, G. K. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-0015-8 · Cited by 11
Self-citation
Cited by
Akiyama, S., Hamdeh, S., Micic, D., & Sakuraba, A. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218946 · Cited by 383
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.057 · Cited by 368
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Li, P., Zheng, Y., & Chen, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00460 · Cited by 346
Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects
Visca, D., Ong, C. W. M., Tiberi, S., Centis, R., D’Ambrosio, L., Chen, B., Mueller, J., Mueller, P., Duarte, R., Dalcolmo, M., et al. (2021) · Pulmonology · doi:10.1016/j.pulmoe.2020.12.012 · Cited by 328
Self-citationTumor Necrosis Factor Receptors: Pleiotropic Signaling Complexes and Their Differential Effects
Gough, P., & Myles, I. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585880 · Cited by 268
Metadata
- Authors
- Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., Marino, V., Matucci, A., Milano, G. M., Tocci, G., Scarpa, R., Goletti, D., & Cantini, F.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2016-12-05
- Volume
- 15
- Issue
- sup1
- Pages
- 11-34
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2559865294
- Cited by
- 308
- References
- 115
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.